Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 21,472 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Graft-versus-host-disease, GVHD
Interventions: Alpha 1-Antitrypsin; Drug
Lead sponsor: John Levine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Endometrial Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more

Conditions: Prostate Cancer
Interventions: C-11 acetate PET scan; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Thrombocytopaenia
Interventions: eltrombopag, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 18
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 15 more

Conditions: Retinitis Pigmentosa
Interventions: Vitamin A, Docosahexaenoic acid, Control fatty acid; Dietary Supplement
Lead sponsor: Carol Weigel DiFranco; NIH
Eligibility: 18 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenovirus Infection
Interventions: Brincidofovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Months and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Feeding, Bottle, Infant, Premature, Diseases, Behavior, Infant
Interventions: Arm 1 - Side-lying position followed by Supine position, Arm 2 - Supine position followed by Side-lying position; Other
Lead sponsor: Boston College; Other
Eligibility: Up to 2 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioma
Interventions: Lenvatinib, Bevacizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Epilepsy in Children, Pharmaco-Resistant Epilepsy
Interventions: Not listed
Lead sponsor: Senda Biosciences; Industry
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Conditions: Persian Gulf Syndrome
Interventions: Aerobic exercise, Cognitive behavioral therapy; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 28
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 18 more

Conditions: Peri-Implantitis
Interventions: Er:YAG Laser, Carbon Fiber Curette; Device · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more

Conditions: Primary Sjögren Syndrome
Interventions: RSLV-132, Placebo; Drug
Lead sponsor: Resolve Therapeutics; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more

Conditions: Post-Ischemic Stroke
Interventions: Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 70
States / cities: Gilbert, Arizona • Berkeley, California • Long Beach, California + 61 more

Conditions: Alzheimer's Disease
Interventions: Aducanumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 104
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more

Conditions: Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions: Chart Review; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myeloid, Acute
Interventions: NLA101, Standard of Care (SOC) chemotherapy; Biological · Drug
Lead sponsor: Nohla Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Brain Tumor
Interventions: Demeclocycline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 80,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more

Conditions: Carotid Stenosis
Interventions: Gadobutrol (Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more

Conditions: Autism Spectrum Disorder
Interventions: Reciprocal Imitation Training; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 16 Months to 33 Months
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • East Lansing, Michigan + 1 more

Conditions: MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Rilotumumab; Drug · Other · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 627
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 402 more

Conditions: Neoplasms
Interventions: RG1530; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 1 more

Search by objective public record fields.

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

Biobehavioral Efficacy of the Semi-Elevated Side-Lying Position

A Study in Subjects With Recurrent Malignant Glioma

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Exercise and Behavioral Therapy Trial (EBT).

Efficacy of Er:YAG Laser in Decontamination of Dental Implants: An In-Vitro Study

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

A Study of RSLV-132 in Females With Sjögren's Disease

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

De-Implementation of Inappropriate Antimicrobial Use After Cardiac Device Procedures

NLA101 in Adults Receiving High Dose Chemotherapy for AML

Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Improving the Part C Early Intervention Service Delivery System for Children With ASD

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.